Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells
出版年份 2020 全文链接
标题
Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells
作者
关键词
-
出版物
CANCER SCIENCE
Volume 111, Issue 8, Pages 2872-2882
出版商
Wiley
发表日期
2020-06-01
DOI
10.1111/cas.14505
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
- (2020) Lei Zhang et al. Molecular Cancer
- Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
- (2020) Jing-Quan Wang et al. Cancers
- Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
- (2020) Zhuo-Xun Wu et al. Cancers
- Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications
- (2019) Yu Toyoda et al. Frontiers in Pharmacology
- The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents
- (2019) Sung-Han Hsiao et al. CANCER LETTERS
- Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
- (2019) Ning Ji et al. Frontiers in Oncology
- Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
- (2019) Zhuo-Xun Wu et al. BIOCHEMICAL PHARMACOLOGY
- Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance
- (2019) Chao-Yun Cai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The role of ABCG2 in modulating responses to anti-cancer photodynamic therapy
- (2019) M. Ibrahim Khot et al. Photodiagnosis and Photodynamic Therapy
- CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2
- (2019) Lejia Xu et al. Molecular Therapy-Oncolytics
- ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients
- (2018) Niclas Björn et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo
- (2018) Guan-Nan Zhang et al. CANCER LETTERS
- Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells
- (2018) Pranav Gupta et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
- (2018) Xiaoran Guo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK2 Inhibitor for Treatment of Triple-negative Breast Cancer with a Compromised G1/S Checkpoint
- (2018) Dan Zhu et al. MOLECULAR CANCER THERAPEUTICS
- Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data?
- (2018) David Ramírez et al. MOLECULES
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis of small-molecule inhibition of human multidrug transporter ABCG2
- (2018) Scott M. Jackson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
- (2018) Karolina Tecza et al. Oncotarget
- Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance
- (2018) Ning Ji et al. BIOCHEMICAL PHARMACOLOGY
- Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells
- (2018) Ning Ji et al. CANCER LETTERS
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
- (2017) Romana-Rea Begicevic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen
- (2017) Jennifer R. Riggs et al. JOURNAL OF MEDICINAL CHEMISTRY
- Localization of the placental BCRP/ ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity
- (2017) John T. Szilagyi et al. PLACENTA
- Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
- (2017) Jun Li et al. Oncotarget
- Membrane Transporters in Physiological Barriers of Pharmacological Importance
- (2016) Ildikó Nagy et al. CURRENT PHARMACEUTICAL DESIGN
- High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer
- (2014) Ken-ichi Fujita et al. LUNG CANCER
- Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
- (2008) Shuji Ota et al. LUNG CANCER
- MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer
- (2008) T. Oguri et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started